Development of resistance to endocrine therapy is a clinical issue in estrogen receptor (ER)-positive breast cancer. Here we show that persistent activation of AKT/mTOR signaling is crucial to the acquisition of letrozole resistance in cell clones generated from MCF-7/AROM-1 aromatase-expressing breast cancer cells after prolonged letrozole exposure. ERα plays a marginal role in this context. As a proof of concept, the association between PI3K/AKT/mTOR signaling and insensitivity to endocrine therapies was confirmed in breast cancer patients who developed early letrozole resistance in neoadjuvant setting. In addition our results suggest that, regardless of the mechanism mediating the activation of AKT/mTOR pathway, either RAD001 or NVP-BEZ235 treatment may represent a promising strategy to overcome acquired resistance to letrozole in breast cancers dependent on AKT/mTOR signaling.

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) / Cavazzoni, Andrea; Bonelli, Mara; Fumarola, Claudia; LA MONICA, Silvia; Airoud, K; Bertoni, R; Alfieri, Roberta; Galetti, Maricla; Tramonti, S; Galvani, Elena; Harris, Al; Martin, La; Andreis, D; Bottini, A; Generali, D; Petronini, Pier Giorgio. - In: CANCER LETTERS. - ISSN 0304-3835. - 323(1):(2012), pp. 77-87. [10.1016/j.canlet.2012.03.034]

Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors)

CAVAZZONI, Andrea;BONELLI, Mara;FUMAROLA, Claudia;LA MONICA, Silvia;ALFIERI, Roberta;GALETTI, Maricla;GALVANI, Elena;PETRONINI, Pier Giorgio
2012-01-01

Abstract

Development of resistance to endocrine therapy is a clinical issue in estrogen receptor (ER)-positive breast cancer. Here we show that persistent activation of AKT/mTOR signaling is crucial to the acquisition of letrozole resistance in cell clones generated from MCF-7/AROM-1 aromatase-expressing breast cancer cells after prolonged letrozole exposure. ERα plays a marginal role in this context. As a proof of concept, the association between PI3K/AKT/mTOR signaling and insensitivity to endocrine therapies was confirmed in breast cancer patients who developed early letrozole resistance in neoadjuvant setting. In addition our results suggest that, regardless of the mechanism mediating the activation of AKT/mTOR pathway, either RAD001 or NVP-BEZ235 treatment may represent a promising strategy to overcome acquired resistance to letrozole in breast cancers dependent on AKT/mTOR signaling.
2012
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) / Cavazzoni, Andrea; Bonelli, Mara; Fumarola, Claudia; LA MONICA, Silvia; Airoud, K; Bertoni, R; Alfieri, Roberta; Galetti, Maricla; Tramonti, S; Galvani, Elena; Harris, Al; Martin, La; Andreis, D; Bottini, A; Generali, D; Petronini, Pier Giorgio. - In: CANCER LETTERS. - ISSN 0304-3835. - 323(1):(2012), pp. 77-87. [10.1016/j.canlet.2012.03.034]
File in questo prodotto:
File Dimensione Formato  
Cancer letters 2012.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.45 MB
Formato Adobe PDF
1.45 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2434770
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 82
  • ???jsp.display-item.citation.isi??? 80
social impact